# ELAINEIII (NCT05696626)

> Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05696626
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: LeonaBio
- Conditions: Metastatic Breast Cancer
- Interventions: Lasofoxifene in combination with abemaciclib; Fulvestrant in combination with abemaciclib
- Enrollment: 600
- Primary outcome: Progression free survival (PFS)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 2
- YouTube: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=elaineiii-nct05696626